WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells
about
May Circulating microRNAs be Gastric Cancer Diagnostic Biomarkers?MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasionAugmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.Suppression of Breast Cancer Metastasis Using Stapled Peptides Targeting the WASF Regulatory Complex.MicroRNA-217 regulates WASF3 expression and suppresses tumor growth and metastasis in osteosarcoma.MicroRNA-200 (miR-200) cluster regulation by achaete scute-like 2 (Ascl2): impact on the epithelial-mesenchymal transition in colon cancer cells.Evaluating human cancer cell metastasis in zebrafish.Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein.Targeting the WASF3-CYFIP1 Complex Using Stapled Peptides Suppresses Cancer Cell Invasion.WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signalingCritical role of the WASF3 gene in JAK2/STAT3 regulation of cancer cell motility.Kisspeptin/KISS1R System in Breast CancerDownregulation of miR-199b is associated with distant metastasis in colorectal cancer via activation of SIRT1 and inhibition of CREB/KISS1 signaling.Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis.Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast texturesSuppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.The involvement of JAK-STAT3 in cell motility, invasion, and metastasis.Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs.Promotion of invasion by mutant RAS is dependent on activation of the WASF3 metastasis promoter gene.The WASF3-NCKAP1-CYFIP1 Complex Is Essential for Breast Cancer Metastasis.Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.WAVE3 Induces EMT and Promotes Migration and Invasion in Intrahepatic Cholangiocarcinoma.A negative feedback loop between miR-200b and the nuclear factor-κB pathway via IKBKB/IKK-β in breast cancer cells.MicroRNA-575 targets BLID to promote growth and invasion of non-small cell lung cancer cells.Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells.Snail-regulated MiR-375 inhibits migration and invasion of gastric cancer cells by targeting JAK2.Entangling Relation of Micro RNA-let7, miRNA-200 and miRNA-125 with Various Cancers.Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma.Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines.Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1α-mediated angiogenesis.Zbtb38 is a novel target for spinal cord injury.HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL.The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase.Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
P2860
Q26780339-47C24844-6A58-40A5-AADE-A4ABE1E5BAC1Q30352893-65BAE2D2-1B2D-4CBE-B136-8E9FA2B408BAQ33792131-96C05DAC-5D53-46FF-8CCE-B21758F675A4Q33824983-6E1625F6-3C35-4DD3-A173-6E489496FDCAQ34301635-D1F28E4E-AC8E-4193-B5FF-4EB0554A91D8Q34774540-80C946AB-CE5E-4215-B085-5A89EC8A2AC0Q35007082-EDE9BAF7-B4DB-4115-97A7-C3CE3D67C46FQ36790655-8104DD54-40D7-4412-B71E-CF9EA8A56E11Q36790763-5C6D81CE-3B0D-4D6D-BE40-78F9F046AC20Q37124053-E844C15A-E595-4273-A435-28FEDEB56DF6Q37151653-D012B692-AAD8-4819-A4B7-318E7C637CDCQ37249506-21899096-ADE8-48A0-952E-40A36699EBFAQ37376470-A7A9A17A-B90A-48D7-BBAF-88E581CCEEFFQ37385242-4B3D269E-4045-4101-BB7D-5A5C2B94EFBCQ37448056-2440C707-C5BD-4B70-A332-CC86C20CF5EDQ37628984-4BC4FD70-7339-431D-A4D4-555B0B7179B1Q38208007-6F37546A-5778-4002-BE11-51DD8E18DF3EQ38223512-6258B852-900F-4C6E-BA2C-2B39C3CB66BEQ38715089-FEEADA0C-4055-4904-8E3E-C31C12D65F7DQ38757069-736469F2-4A11-4422-A47F-01950896D0B3Q38770633-4061279A-417D-4957-A56E-A1F9F4F1D624Q38786803-6A99AE16-9CE5-4F4A-A57F-EB8B7D57CF8DQ38830564-479C4319-32B1-4BEB-AC37-73404813BE04Q38904926-2F62F855-5379-41F5-B67D-A3638260474EQ38949698-7903D346-613C-4384-A21F-BBD477044DF7Q38972399-0C8DA762-016E-49F2-AD21-AFDD107AC8ECQ39077807-567D83BE-4B26-40B1-A66C-C74EE1BBD308Q40211104-B2C38D54-6D0E-430D-91EB-9F929E44A7B1Q40283731-40C9FA7F-43CF-4807-9DDD-B686D7A2DC5DQ40492761-56FEF069-0F1D-4A4E-8B84-8BA1BDB066EEQ41233374-9F67D911-83DC-4F70-8B03-6EA0E973BBB7Q47385628-A94006B6-DFD9-472D-9648-83C141C0F166Q49723864-B95FAC5C-1040-4A8C-AF01-1C976113C3E6Q55450651-84B59C34-1D0A-4BDC-8BE6-F89328AAE026
P2860
WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
WASF3 regulates miR-200 inacti ...... iveness in breast cancer cells
@en
WASF3 regulates miR-200 inacti ...... veness in breast cancer cells.
@nl
type
label
WASF3 regulates miR-200 inacti ...... iveness in breast cancer cells
@en
WASF3 regulates miR-200 inacti ...... veness in breast cancer cells.
@nl
prefLabel
WASF3 regulates miR-200 inacti ...... iveness in breast cancer cells
@en
WASF3 regulates miR-200 inacti ...... veness in breast cancer cells.
@nl
P2860
P356
P1433
P1476
WASF3 regulates miR-200 inacti ...... iveness in breast cancer cells
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2012.565
P407
P577
2013-01-14T00:00:00Z